Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Auxly Cannabis Group (CBWTF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Auxly Cannabis Group $0.60, price $2.40, upside -75.0%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
AC
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
Auxly Cannabis Group
CBWTF · USStretched ValuationQuality growthStrong overvaluation with only moderate quality.
!Fair value $0.6000 · Strongly overvalued (−75.0%)
!Quality 58/100
✓Healthy Growth (revenue 5y +24.4 %/yr)
✓Highly profitable · 20.9% net margin (TTM)
✓Low debt · generates free cash flow
!Moderate moat 64/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0130 – $3.72 · fair‑value band $0.3000 – $0.7400 · the $2.40 price screens above the $0.6000 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company offers dried and fresh cannabis, plants, seeds, and oils; and edibles, extracts, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names.
Show more
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company offers dried and fresh cannabis, plants, seeds, and oils; and edibles, extracts, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Toronto, Canada.
Stock analysis
Auxly Cannabis Group (CBWTF) currently trades at $2.40, while our model-based Fair Value estimate is $0.6000, 75.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.9500 per share, and 0 of the 24 models we run sit above the $2.40 price.
Bear case: the Asset-Based group reads lowest at $0.0600, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $0.3000 (bear) to $0.7400 (bull), the price of $2.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Auxly Cannabis Group reported revenue of C$151M in FY2025 versus C$83.8M in FY2021, a compound +15.9%/yr. Reported net income was C$41.9M in FY2025.
Key figures
Market cap $173M · P/E ratio 12.1 · P/S ratio 3.34 · EPS (TTM) $0.0100 · Net margin 27.6% · Return on equity 21.3% · Return on assets (EBIT) −3.1% · Operating margin 11.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 105% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −75%, CBWTF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.0600 to $0.9700). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $0.3000
Fair Value $0.6000
Bull $0.7400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0076 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.1700
$0.2400
$0.4400
75
EPV
$0.1000
$0.1100
$0.1200
74
Growth DCF
$0.1600
$0.2500
$0.4100
74
All 24 models by family
DCF Models
FCF DCF
$0.1700
$0.2400
$0.4400
75
Owner Earnings
$0.3000
$0.6000
$1.12
70
5Y Revenue Exit
$0.1600
$0.2700
$0.5100
67
5Y EBITDA Exit
$0.2000
$0.3600
$0.6800
69
5Y P/E Exit
$0.2800
$0.6400
$1.14
65
10Y Revenue Exit
$0.1600
$0.3300
$0.4300
64
10Y EBITDA Exit
$0.1900
$0.4100
$0.8000
62
10Y P/E Exit
$0.2300
$0.5400
$1.06
58
Earnings-Based
Graham-Dodd
$0.1400
$0.9700
$1.36
61
Lynch FV
$0.5000
$0.7200
$0.9300
59
PEG = 1.0
$0.5000
$0.7200
$0.9300
55
EPV
$0.1000
$0.1100
$0.1200
74
Multiples
P/E Multiple
$0.3400
$0.4500
$0.5600
63
P/S Multiple
$0.1900
$0.2600
$0.3200
58
P/B Multiple
$0.2600
$0.3500
$0.4400
55
EV/EBIT
$0.2000
$0.2700
$0.3400
66
EV/EBITDA
$0.2200
$0.3000
$0.3700
67
EV/Revenue
$0.1400
$0.2000
$0.2700
53
Asset-Based
NCAV (Graham)
$0.0400
$0.0600
$0.0900
53
Growth DCF
Growth DCF
$0.1600
$0.2500
$0.4100
74
Rev-Margin DCF
$0.1700
$0.3100
$0.5900
67
Economic Profit
Residual Income
$0.1000
$0.1400
$0.2400
65
ROIC Compounder
$0.1100
$0.1400
$0.1700
70
Growth Earnings
Growth-Adj P/E
$0.6700
$0.9500
$1.24
65
Notify me when CBWTF reaches fair value
Put CBWTF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
58/100
Of which business quality 57 · Market factors (momentum, volatility) 75
Profitability
73
Margins and returns on capital today
Quality Growth
78
Are margins and returns improving?
Cashflow
58
Earnings quality: real cash, not paper profit
Fin. Strength
48
Balance sheet, leverage, solvency risk
Investment
67
Disciplined investing over empire-building
Low Volatility
28
Calm price path (market factor)
Momentum
97
Price trend over the last 3–12 months (market factor)
52W Momentum
92
Distance to the 52-week high (market factor)
Net Issuance
18
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+23.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.4%
Start year 2020 (pandemic). Over 10 years: +89.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−92.7% (2020) → 21.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+59.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +56.1% a year for the price.
CBWTF screens overvalued: fair value 75% below the price. Compare with Merck KGaA →
Compare Auxly Cannabis Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €134.45 | €108.94 | −19% |
| Takeda Pharmaceutical Company TAK | $18.90 | $11.45 | −39% |
| Teva Pharmaceutical Industries Limited TEVA | $39.31 | $20.88 | −47% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,852 | ₹1,979 | +7% |
| Galderma Group GALD | CHF 163.00 | CHF 110.32 | −32% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥44.86 | ¥49.35 | +10% |
| Haleon plc HLN | $9.26 | $8.49 | −8% |
| Sandoz Group SDZ | CHF 71.16 | CHF 40.32 | −43% |
| Zoetis Inc ZTS | $70.30 | $110.50 | +57% |
| Divi's Laboratories Limited DIVISLAB | ₹9,620 | ₹1,871 | −81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Auxly Cannabis Group (CBWTF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.6000 versus a price of $2.40, about −75% upside (overvalued).
What is the fair value of CBWTF?
Our model-based fair value for Auxly Cannabis Group is $0.6000 (as of Sep 24, 2026), built from audited fundamentals. The current price: $2.40.
What is the quality score of CBWTF?
Auxly Cannabis Group has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Auxly Cannabis Group (CBWTF)?
Our model-based price target is the fair value of $0.6000 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.3000, optimistic scenario $0.7400. It is a calculation from audited fundamentals, not an analyst target.
What is the Auxly Cannabis Group stock forecast for 2026?
Our models put fair value at $0.6000, about −75% upside versus a price of $2.40 (overvalued). Cautious scenario $0.3000, optimistic scenario $0.7400. The calculation is refreshed regularly with new filings.
What is the revenue of Auxly Cannabis Group (CBWTF)?
Auxly Cannabis Group reported trailing-twelve-month revenue of about $159M (latest available figure, as of Sep 24, 2026).
What growth is priced into Auxly Cannabis Group (CBWTF)?
For today's price to be fair in a discounted-cash-flow model, Auxly Cannabis Group would have to grow free cash flow by +59.8 % per year for five years (discount rate 13.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CBWTF use?
Our models discount Auxly Cannabis Group at 13.2 %: a base by market capitalisation (micro), damped by beta 1.16, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Auxly Cannabis Group that is +59.8 % per year a year over ten years, using the same discount rate (13.2 %) and the same formula as our fair value.
How much growth has Auxly Cannabis Group (CBWTF) delivered so far?
Over the past 5 years revenue at Auxly Cannabis Group grew +24.4 % a year. The price currently implies +59.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Auxly Cannabis Group (CBWTF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Auxly Cannabis Group (+59.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Auxly Cannabis Group (CBWTF)?
The free-cash-flow yield on the price is 0.72 %: that much free cash flow Auxly Cannabis Group produces per unit of market value. When it exceeds the discount rate of our models (13.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Auxly Cannabis Group (CBWTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Auxly Cannabis Group it is $0.6000 per share (as of Sep 24, 2026), against a price of $2.40. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Auxly Cannabis Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CBWTF trades above its calculated fair value: price $2.40, fair value $0.6000, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CBWTF?
No. The price is what the market pays today ($2.40); the fair value is what the company's own numbers justify ($0.6000). For Auxly Cannabis Group the two are $1.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Auxly Cannabis Group worth?
The market values Auxly Cannabis Group at about $173M (market capitalisation, as of Sep 24, 2026). Per share that is $2.40; our models calculate a fair value of $0.6000 per share.
What do the bullish and bearish scenarios say about CBWTF?
Our models span a range for Auxly Cannabis Group: cautious scenario $0.3000, base $0.6000, optimistic $0.7400 per share (as of Sep 24, 2026, price $2.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is CBWTF from its 52-week high?
Auxly Cannabis Group trades at $2.40, about 9% below its 52-week high of $2.65 and 105% above the low of $1.17 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6000 is for.
Which stocks are comparable to Auxly Cannabis Group?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Auxly Cannabis Group stock attractive at the current price?
The data as of Sep 24, 2026: price $2.40, calculated fair value $0.6000 (−75%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CBWTF calculated?
We run Auxly Cannabis Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Auxly Cannabis Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Auxly Cannabis Group (CBWTF)?
The closing price on Oct 2, 2026 was $2.40. Our model-based fair value is $0.6000, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Auxly Cannabis Group right now?
The price sits above even our optimistic bull case ($0.7400). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.3000 to $0.7400) leaves room in how you read the outcome.
Key figures of Auxly Cannabis Group
How large is the market capitalisation of Auxly Cannabis Group (CBWTF)?
The market capitalisation of Auxly Cannabis Group is $173M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Auxly Cannabis Group (CBWTF)?
The price-to-earnings ratio of Auxly Cannabis Group is 12.1 (as of Jun 19, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Auxly Cannabis Group (CBWTF)?
The price-to-sales ratio of Auxly Cannabis Group is 3.34 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Auxly Cannabis Group (CBWTF)?
Earnings per share at Auxly Cannabis Group are $0.0100 (price ÷ EPS = P/E 12.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Auxly Cannabis Group (CBWTF)?
The net margin of Auxly Cannabis Group is 27.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Auxly Cannabis Group (CBWTF)?
The return on equity (ROE) of Auxly Cannabis Group is 21.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Auxly Cannabis Group (CBWTF)?
On an EBIT basis the return on assets of Auxly Cannabis Group is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Auxly Cannabis Group (CBWTF)?
The operating margin of Auxly Cannabis Group is 11.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Auxly Cannabis Group (CBWTF)?
Revenue at Auxly Cannabis Group is growing +21.7% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Auxly Cannabis Group (CBWTF)?
Earnings per share at Auxly Cannabis Group are growing −76.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Auxly Cannabis Group (CBWTF) carry?
The net debt of Auxly Cannabis Group is $14.0M (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.